Health Canada seeks public input on a proposed review queue pilot designed to strengthen supply security and reduce drug shortage risks.
Unapproved obesity drug retatrutide is fueling a fast-growing black market of counterfeit products, exposing gaps in the regulatory system as federal agencies struggle to keep up.
White House health adviser Heidi Overton is set to be nominated to lead the FDA, succeeding Marty Makary amid agency turnover and ongoing policy disputes.
Our in-brief roundup of notable healthcare and life sciences stories from the last two weeks.
The Third Circuit has ruled a fax about a blood thinner could qualify as an unsolicited advertisement under the TCPA.
A new study found proposed Medicare drug pricing models may rely on prices from relatively few international markets.
Case examines allegations involving AstraZeneca under the ABPI Code, underscoring the compliance controls drugmakers need to implement.
Analysing the compliance imperatives for both US pharma and the strategic considerations for Chinese biotech navigating the cross-border environment.
